Product nameAnti-FGF9/GAF antibody [EPR19937] - BSA and Azide free
See all FGF9/GAF primary antibodies
DescriptionRabbit monoclonal [EPR19937] to FGF9/GAF - BSA and Azide free
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Recombinant fragment aa 1 to the C-terminus. The exact sequence is proprietary. Mature protein without the proprotein from aa 1-3.
Database link: P31371
- WB: Human FGF9/GAF active protein; human fetal brain, fetal kidney and ovary cancer lysates; mouse kidney and brain lysates; rat brain lysate; C6, PC-12, NIH/3T3 and U-87 MG whole cell lysates.
ab223543 is the carrier-free version of ab206408 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Ab223543 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
Previously labelled as FGF9.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab223543 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 26 kDa (predicted molecular weight: 23 kDa).|
FunctionMay have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
Tissue specificityGlial cells.
Involvement in diseaseDefects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
Sequence similaritiesBelongs to the heparin-binding growth factors family.
modificationsThree molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
- Information by UniProt
- FGF 9 antibody
- FGF-9 antibody
- FGF9 antibody
All lanes : Anti-FGF9/GAF antibody [EPR19937] (ab206408)
Lane 1 : Human FGF16/GAF recombinant protein
Lanes 2-3 : Human FGF9/GAF active protein
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Predicted band size: 23 kDa
Observed band size: 23 kDa
This WB data was generated using the same anti-FGF9/GAF antibody clone [EPR19937] in a different buffer formulation (cat# ab206408).
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1/2: 1 seconds; Lane 3: 15 seconds.
Human FGF9/GAF active protein contains aa1-208; FGF16 and FGF20 recombinant protein contain aa1-203 and aa4-208 respectively, both with His-Tag®.
ab223543 has not yet been referenced specifically in any publications.